人血浆中α2-纤溶酶抑制剂的不同N端形式。
Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma.
作者信息
Bangert K, Johnsen A H, Christensen U, Thorsen S
机构信息
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
出版信息
Biochem J. 1993 Apr 15;291 ( Pt 2)(Pt 2):623-5. doi: 10.1042/bj2910623.
Abstract
Mature alpha 2-plasmin inhibitor in human plasma has 12 more N-terminal residues than hitherto anticipated. The first residue is the methionine at position 28, downstream from the N-terminus of the pre-protein. The cDNA sequence predicts that the site cleaved upon formation of the mature inhibitor is a typical signal-peptidase recognition site. The mature inhibitor (464 residues) and the previously reported, and presumably degraded, form with N-terminal asparagine (452 residues), are present in plasma in about equal amounts. They both form a stable complex with plasmin. Recent studies on a recombinant alpha 2-plasmin inhibitor suggest that the 12 additional residues have functional implications [Sumi, Ichikawa, Nakamura, Miura and Aoki (1989) J. Biochem. 106, 703-707].
摘要
人血浆中的成熟α2-纤溶酶抑制剂比迄今预期的多12个N端残基。第一个残基是第28位的甲硫氨酸，位于前体蛋白N端下游。cDNA序列预测，成熟抑制剂形成时切割的位点是典型的信号肽酶识别位点。成熟抑制剂（464个残基）和先前报道的、可能已降解的N端天冬酰胺形式（452个残基）在血浆中的含量大致相等。它们都与纤溶酶形成稳定的复合物。最近对重组α2-纤溶酶抑制剂的研究表明，额外的12个残基具有功能意义[Sumi、Ichikawa、Nakamura、Miura和Aoki（1989年）《生物化学杂志》106，703 - 707]。
相似文献
1
Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma.
Biochem J. 1993 Apr 15;291 ( Pt 2)(Pt 2):623-5. doi: 10.1042/bj2910623.
2
Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.
Biochem J. 1988 Oct 15;255(2):609-15.
3
Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells.
Biochem Biophys Res Commun. 1994 Apr 15;200(1):417-22. doi: 10.1006/bbrc.1994.1465.
4
Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
Biochem J. 1984 Oct 1;223(1):169-77. doi: 10.1042/bj2230169.
5
Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.
Blood. 2016 Feb 4;127(5):538-45. doi: 10.1182/blood-2015-09-670117. Epub 2015 Dec 1.
6
Purification of human alpha 2-antiplasmin with chicken IgY specific to its carboxy-terminal peptide.
Prep Biochem Biotechnol. 1997 Nov;27(4):227-37. doi: 10.1080/10826069708001281.
7
Purification and partial characterisation of alpha(2)-antiplasmin and plasmin(ogen) from ostrich plasma.
Comp Biochem Physiol B Biochem Mol Biol. 2001 Jul;129(4):809-20. doi: 10.1016/s1096-4959(01)00396-7.
8
Contribution of conserved lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition.
J Biol Chem. 2011 Jul 15;286(28):24544-52. doi: 10.1074/jbc.M111.229013. Epub 2011 May 4.
9
Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).
J Biol Chem. 1987 Feb 5;262(4):1659-64.
10
Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
Biochem J. 1981 Sep 1;197(3):619-28. doi: 10.1042/bj1970619.
引用本文的文献
1
Effect of Alpha2-Plasmin Inhibitor C-Terminal Heterogeneity on Clot Lysis and Clot Structure.
Biomolecules. 2025 Aug 5;15(8):1127. doi: 10.3390/biom15081127.
2
Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.
TH Open. 2022 Nov 18;6(4):e396-e407. doi: 10.1055/a-1957-6817. eCollection 2022 Oct.
3
Low α2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis.
Front Cardiovasc Med. 2022 Jul 15;9:901286. doi: 10.3389/fcvm.2022.901286. eCollection 2022.
4
Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.
Int J Mol Sci. 2021 Nov 21;22(22):12537. doi: 10.3390/ijms222212537.
5
Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.
Int J Mol Sci. 2021 Mar 17;22(6):3055. doi: 10.3390/ijms22063055.
6
Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Biomolecules. 2021 Feb 25;11(3):347. doi: 10.3390/biom11030347.
7
Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease.
Front Cardiovasc Med. 2020 Dec 23;7:608899. doi: 10.3389/fcvm.2020.608899. eCollection 2020.
8
Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure.
EJIFCC. 2001 Jul 22;13(2):61-66. eCollection 2001 Jul.
9
Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery.
Thromb Haemost. 2018 Sep;118(9):1545-1555. doi: 10.1055/s-0038-1667198. Epub 2018 Aug 7.
10
Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.
PLoS One. 2018 May 3;13(5):e0196911. doi: 10.1371/journal.pone.0196911. eCollection 2018.
本文引用的文献
1
Demonstration of two forms of alpha 2-antiplasmin in plasma by modified crossed immunoelectrophoresis.
Thromb Res. 1981;21(1-2):65-71. doi: 10.1016/0049-3848(84)90033-1.
2
Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
J Clin Invest. 1982 Mar;69(3):536-42. doi: 10.1172/jci110479.
3
Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
J Biol Chem. 1982 Aug 25;257(16):9849-54.
4
Affinity-chromatographic purification of human alpha 2-antiplasmin.
Biochem J. 1980 Oct 1;191(1):229-32. doi: 10.1042/bj1910229.
5
Properties of three different molecular forms of the alpha 2 plasmin inhibitor.
Eur J Biochem. 1981 Nov;120(1):105-12. doi: 10.1111/j.1432-1033.1981.tb05675.x.
6
Inhibitors of the fibrinolytic enzyme system.
Semin Thromb Hemost. 1984 Jan;10(1):24-41. doi: 10.1055/s-2007-1004405.
7
A new method for predicting signal sequence cleavage sites.
Nucleic Acids Res. 1986 Jun 11;14(11):4683-90. doi: 10.1093/nar/14.11.4683.
8
The course and prerequisites of Lys-plasminogen formation during fibrinolysis.
Biochemistry. 1988 Apr 5;27(7):2435-43. doi: 10.1021/bi00407a029.
9
Structure of human alpha 2-plasmin inhibitor deduced from the cDNA sequence.
J Biochem. 1987 Nov;102(5):1033-41. doi: 10.1093/oxfordjournals.jbchem.a122141.
10
The microheterogeneity of desialylated alpha 1-antichymotrypsin: the occurrence of two amino-terminal isoforms, one lacking a His-Pro dipeptide.
Biochim Biophys Acta. 1989 Jul 27;997(1-2):90-5. doi: 10.1016/0167-4838(89)90139-8.
Zotero 插件